Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Spironolactone Orion

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Spironolakton Testmiljö

Spironolakton

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens. 2013;31:3-15.

  2. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST et al. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2008;21:61-6.

  3. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820-5.

  4. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-45.

  5. Vaclavik J, Sedlak R, Jarkovsky J, Kocianova E, Taborsky M. Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: insights from the aspirant trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(3):384-90.

  6. Olivieri O, Pizzolo F, Ciacciarelli A, Corrocher R, Signorelli D, Falcone S et al. Menopause not aldosterone-to-renin ratio predicts blood pressure response to a mineralocorticoid receptor antagonist in primary care hypertensive patients. Am J Hypertens. 2008;21:976-82.

  7. Aldactone (spironolactone) DailyMed 2018. DailyMed [www]. US National Library of Medicine. [updated 2018-09-05, cited 2019-03-04].

  8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17.

  9. Opasich C, De Feo S, Ambrosio GA, Bellis P, Di Lenarda A, Di Tano G et al. The 'real' woman with heart failure Impact of sex on current in-hospital management of heart failure by cardiologists and internists. Eur J Heart Fail. 2004;6:769-79.

  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]

  1. Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens. 2013;31:3-15.
  2. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST et al. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2008;21:61-6.
  3. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820-5.
  4. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-45.
  5. Vaclavik J, Sedlak R, Jarkovsky J, Kocianova E, Taborsky M. Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: insights from the aspirant trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(3):384-90.
  6. Olivieri O, Pizzolo F, Ciacciarelli A, Corrocher R, Signorelli D, Falcone S et al. Menopause not aldosterone-to-renin ratio predicts blood pressure response to a mineralocorticoid receptor antagonist in primary care hypertensive patients. Am J Hypertens. 2008;21:976-82.
  7. Aldactone (spironolactone) DailyMed 2018. DailyMed [www]. US National Library of Medicine. [updated 2018-09-05, cited 2019-03-04].
  8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17.
  9. Opasich C, De Feo S, Ambrosio GA, Bellis P, Di Lenarda A, Di Tano G et al. The 'real' woman with heart failure Impact of sex on current in-hospital management of heart failure by cardiologists and internists. Eur J Heart Fail. 2004;6:769-79.
  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]